93 related articles for article (PubMed ID: 24734524)
1. Enhancing proteasome-lnhibitor effect by functionalized gold nanoparticles.
Coelho SC; Rocha S; Pereira MC; Juzenas P; Coelho MA
J Biomed Nanotechnol; 2014 Apr; 10(4):717-23. PubMed ID: 24734524
[TBL] [Abstract][Full Text] [Related]
2. Gold nanoparticle delivery-enhanced proteasome inhibitor effect in adenocarcinoma cells.
Coelho SC; Rocha S; Juzenas P; Sampaio P; Almeida GM; Silva FS; Pereira MC; Coelho MA
Expert Opin Drug Deliv; 2013 Oct; 10(10):1345-52. PubMed ID: 23937147
[TBL] [Abstract][Full Text] [Related]
3. Synergistic anticancer activity of combined histone deacetylase and proteasomal inhibitor-loaded zein nanoparticles in metastatic prostate cancers.
Thapa RK; Nguyen HT; Jeong JH; Shin BS; Ku SK; Choi HG; Yong CS; Kim JO
Nanomedicine; 2017 Apr; 13(3):885-896. PubMed ID: 27993720
[TBL] [Abstract][Full Text] [Related]
4. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer.
An J; Sun YP; Adams J; Fisher M; Belldegrun A; Rettig MB
Clin Cancer Res; 2003 Oct; 9(12):4537-45. PubMed ID: 14555528
[TBL] [Abstract][Full Text] [Related]
5. Apoptotic effects of proteasome and histone deacetylase inhibitors in prostate cancer cell lines.
Kiliccioglu I; Konac E; Varol N; Gurocak S; Yucel Bilen C
Genet Mol Res; 2014 May; 13(2):3721-31. PubMed ID: 24854658
[TBL] [Abstract][Full Text] [Related]
6. The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma.
Hutter G; Rieken M; Pastore A; Weigert O; Zimmermann Y; Weinkauf M; Hiddemann W; Dreyling M
Ann Hematol; 2012 Jun; 91(6):847-56. PubMed ID: 22231280
[TBL] [Abstract][Full Text] [Related]
7. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma.
Paoluzzi L; Scotto L; Marchi E; Zain J; Seshan VE; O'Connor OA
Clin Cancer Res; 2010 Jan; 16(2):554-65. PubMed ID: 20068080
[TBL] [Abstract][Full Text] [Related]
8. Thiazole antibiotic thiostrepton synergize with bortezomib to induce apoptosis in cancer cells.
Pandit B; Gartel AL
PLoS One; 2011 Feb; 6(2):e17110. PubMed ID: 21365012
[TBL] [Abstract][Full Text] [Related]
9. Protective role of humanin on bortezomib-induced bone growth impairment in anticancer treatment.
Eriksson E; Wickström M; Perup LS; Johnsen JI; Eksborg S; Kogner P; Sävendahl L
J Natl Cancer Inst; 2014 Mar; 106(3):djt459. PubMed ID: 24586107
[TBL] [Abstract][Full Text] [Related]
10. Enhancing the efficiency of bortezomib conjugated to pegylated gold nanoparticles: an in vitro study on human pancreatic cancer cells and adenocarcinoma human lung alveolar basal epithelial cells.
Coelho SC; Almeida GM; Santos-Silva F; Pereira MC; Coelho MA
Expert Opin Drug Deliv; 2016 Aug; 13(8):1075-81. PubMed ID: 27087021
[TBL] [Abstract][Full Text] [Related]
11. [Proteasome inhibitors].
Alexandre J
Rev Med Interne; 2005 Oct; 26(10):812-5. PubMed ID: 16129520
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms.
Takigawa N; Vaziri SA; Grabowski DR; Chikamori K; Rybicki LR; Bukowski RM; Ganapathi MK; Ganapathi R; Mekhail T
Anticancer Res; 2006; 26(3A):1869-76. PubMed ID: 16827119
[TBL] [Abstract][Full Text] [Related]
13. Efficient bioactive delivery of aerosolized drugs to human pulmonary epithelial cells cultured in air-liquid interface conditions.
Lenz AG; Stoeger T; Cei D; Schmidmeir M; Semren N; Burgstaller G; Lentner B; Eickelberg O; Meiners S; Schmid O
Am J Respir Cell Mol Biol; 2014 Oct; 51(4):526-35. PubMed ID: 24773184
[TBL] [Abstract][Full Text] [Related]
14. A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity.
Kobrinsky B; Joseph SO; Muggia F; Liebes L; Beric A; Malankar A; Ivy P; Hochster H
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1073-8. PubMed ID: 24048674
[TBL] [Abstract][Full Text] [Related]
15. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.
Cusack JC; Liu R; Houston M; Abendroth K; Elliott PJ; Adams J; Baldwin AS
Cancer Res; 2001 May; 61(9):3535-40. PubMed ID: 11325813
[TBL] [Abstract][Full Text] [Related]
16. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
17. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib primes neuroblastoma cells for TRAIL-induced apoptosis by linking the death receptor to the mitochondrial pathway.
Naumann I; Kappler R; von Schweinitz D; Debatin KM; Fulda S
Clin Cancer Res; 2011 May; 17(10):3204-18. PubMed ID: 21459798
[TBL] [Abstract][Full Text] [Related]
19. Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells.
Nencioni A; Wille L; Dal Bello G; Boy D; Cirmena G; Wesselborg S; Belka C; Brossart P; Patrone F; Ballestrero A
Clin Cancer Res; 2005 Jun; 11(11):4259-65. PubMed ID: 15930365
[TBL] [Abstract][Full Text] [Related]
20. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma.
Weigert O; Pastore A; Rieken M; Lang N; Hiddemann W; Dreyling M
Leukemia; 2007 Mar; 21(3):524-8. PubMed ID: 17268531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
